All Curated Mutation Sites in SARS-CoV-2

Back to Mutation Home

The Virus Mutation(VM) module provides researchers the annotations of reported pathogenic mutations in SARS-CoV-2 related to human diseases. The curated VM information includes mutation site, mutation level, virus gene/protein/region, virus-associated disease, genotype/subtype, literature evidence, etc.

Browse Data by Virus Gene/Protein/Region, Disease OR Description

*Please select one option you are interested in, the page will be automatically redirected.

Virus Gene/Protein

Disease

Description

For highly variable viruses (e.g., HBV, HIV, SARS-CoV-2), ViMIC defaults to displaying mutations in a specific region. Click the green button to search for other regions, or click "Show All" to view all mutations (loading speed may be affected by network conditions).

Furin cleavage site

Methyltransferase

Non-coding region

Keyword: NSP9

ID	PMID	Mutation	Gene/Protein/Region	Encoding Gene/Protein	Disease	Description	Detail
1	39048693	T35I	NSP9	ORF1a	Cell line	R L	View
2	39048693	C12789T	NSP9	ORF1a	Cell line	R L	View
3	36512569	C12970T	NSP9	ORF1a		G R L	View
4	36512569	C12933T	NSP9	ORF1a		G R L	View
5	36512569	N95N	NSP9	ORF1a		G R L	View
6	36512569	P83L	NSP9	ORF1a		G R L	View
7	35624123	G37E	NSP9	ORF1a		R	View
8	39146693	T35I	NSP9	ORF1a	COVID-19	G L	View
9	38605705	T35I	NSP9;NSP16	ORF1ab	COVID-19	G R S C L	View
10	38605705	C12789T	NSP9	ORF1a	COVID-19	G R S C L	View
11	37224159	T19I	S;NSP9	S;ORF1a	COVID-19	G R L	View
12	37224159	C12741T	NSP9	ORF1a	COVID-19	G R L	View
13	37224159	C12880T	NSP9	ORF1a	COVID-19	G R L	View
14	37224159	I65I	NSP9	ORF1a	COVID-19	G R L	View
15	39227954	T35I	NSP9	ORF1a	COVID-19	G R L	View
16	38791536	G37E	NSP9	ORF1a	COVID-19	R L	View
17	38605705	C12880T	NSP9	ORF1a	COVID-19	G R S C L	View
18	36841805	T35I	NSP9	ORF1a	COVID-19	R	View
19	33384909	G4177E	NSP9	ORF1a	COVID-19	R	View
20	37529147	I65I	NSP9	ORF1a	COVID-19	R S L	View
21	38435775	R39K	NSP9	ORF1a	COVID-19	C L	View

Contents
Description

The table shows all curated mutation sites of SARS-CoV-2 in each literature

Table Description Column Note

D
The study mentioned a certain treatment method, such as drug resistance caused by mutations.

G
The study mentioned the virus genotype/subtype information.

R
The study mentioned the reference sequence used for comparison, or the original strain of the virus used for site-directed mutagenesis.

S
The study provided sequence information or accession numbers.

L
The study provided the geographic region/country of data origin.

C
The study provided clinical baseline information.

I
The study involved information related to immune.

T
The study involved host target genes.